Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.
Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
Nat Cancer. 2020 Nov;1(11):1097-1112. doi: 10.1038/s43018-020-00121-4. Epub 2020 Oct 26.
Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor microenvironment that renders it largely refractory to immunotherapy. We implemented a multimodal analysis approach to elucidate the immune landscape in PDA. Using a combination of CyTOF, single-cell RNA sequencing, and multiplex immunohistochemistry on patient tumors, matched blood, and non-malignant samples, we uncovered a complex network of immune-suppressive cellular interactions. These experiments revealed heterogeneous expression of immune checkpoint receptors in individual patient's T cells and increased markers of CD8 T cell dysfunction in advanced disease stage. Tumor-infiltrating CD8 T cells had an increased proportion of cells expressing an exhausted expression profile that included upregulation of the immune checkpoint , a finding that we validated at the protein level. Our findings point to a profound alteration of the immune landscape of tumors, and to patient-specific immune changes that should be taken into account as combination immunotherapy becomes available for pancreatic cancer.
胰腺导管腺癌 (PDA) 的特征是免疫抑制性肿瘤微环境,使其对免疫疗法基本产生抗性。我们采用多模式分析方法来阐明 PDA 的免疫景观。我们使用 CyTOF、单细胞 RNA 测序和对患者肿瘤、匹配血液和非恶性样本的多重免疫组化相结合的方法,揭示了免疫抑制性细胞相互作用的复杂网络。这些实验揭示了个体患者 T 细胞中免疫检查点受体的异质性表达,并在晚期疾病阶段增加了 CD8 T 细胞功能障碍的标志物。肿瘤浸润性 CD8 T 细胞中表达耗尽表型的细胞比例增加,包括上调免疫检查点,这一发现我们在蛋白质水平上进行了验证。我们的研究结果表明肿瘤的免疫景观发生了深刻的改变,并且随着联合免疫疗法可用于胰腺癌,患者特异性免疫变化也应被考虑在内。